Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trialLucia Del Mastro, Paolo Bruzzi, Mauro Mansutti et al.|The Lancet Oncology|2021Cited by 86
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozoleGianluigi Lunardi, Lucia Del Mastro, Mauro Porpiglia et al.|Breast Cancer Research and Treatment|2012Cited by 23
Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM).Lucia Del Mastro, Francesca Poggio, Mauro Mansutti et al.|Journal of Clinical Oncology|2019Cited by 13
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 TrialsBenedetta Conte, Lucia Del Mastro, Luca Boni et al.|Clinical Cancer Research|2023Cited by 7
118O Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano MammellaLucia Del Mastro, Paolo Bruzzi, Mauro Mansutti et al.|Annals of Oncology|2021Cited by 1